510(k) device
VISCO 360 Viscosurgical System
Sight Sciences, Inc. · Pump, Infusion, Ophthalmic (MRH, Class II) · First FDA decision Jul 27, 2017, newest Jul 27, 2017Glaucoma
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "VISCO 360 Viscosurgical"
MAUDE reports
0
Brand "VISCO 360 Viscosurgical", since 2015
PubMed studies
0
Mentioning "VISCO 360 Viscosurgical"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing VISCO 360 Viscosurgical System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K171905 · Decided Jul 27, 2017 · 31 days after receipt
Device type: Pump, Infusion, Ophthalmic (MRH) · Hospital Medicine & Nursing
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "VISCO 360 Viscosurgical", any status and sponsor, newest update first.
- Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle GlaucomaTerminated
Sight Sciences, Inc.Not on our public-company list
NCT02928289 · 29 participants · Start Jan 23, 2017 · Primary completion Jan 17, 2019
Device: VISCO360 ab interno canaloplasty surgery; Selective Laser Trabeculoplasty (SLT) · For: Open-Angle Glaucoma
Sites: Fayetteville, Arkansas; Orange, California; Oklahoma City, Oklahoma · 6 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "VISCO 360 Viscosurgical", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MRH
140 reports: 44 malfunction, 95 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "VISCO 360 Viscosurgical"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MRH.
- OMNI Surgical SystemSight Sciences, Inc. · 510(k) 2023
- Viscoelastic InjectorSight Sciences, Inc. · 510(k) 2014
- OMNI Ultra Surgical System (1-110)Sight Sciences, Inc. · 510(k) 2026
- VIA360 Surgical SystemNew World Medical, Inc. · 510(k) 2025
- TrabEx ProMicrosurgical Technologies, Inc. · 510(k) 2022
- iPrime Viscodelivery SystemGlaukos · 510(k) 2022
- Streamline Surgical SystemNew World Medical, Inc. · 510(k) 2021
- OMNI PLUS Surgical SystemSight Sciences, Inc. · 510(k) 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.